Welcome to our dedicated page for ARCELLX news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on ARCELLX stock.
Arcellx Inc. (ACLX) is a clinical-stage biotechnology company pioneering controllable cell therapies for cancer and complex diseases. This page aggregates official press releases and verified news about ACLX's immunotherapy advancements, clinical trial progress, and regulatory developments.
Investors and researchers will find timely updates on key milestones including trial results, partnership announcements, and FDA communications. Our curated collection spans therapeutic innovations in multiple myeloma, acute myeloid leukemia, and emerging cell therapy platforms.
All content is sourced directly from company filings and reputable financial publications. Bookmark this page for centralized access to ACLX's latest scientific breakthroughs and strategic business decisions in the evolving cell therapy landscape.
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology firm specializing in immunotherapies for cancer and other severe diseases, will participate in the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on April 20, 2023, at 1:00 p.m. ET. This session will be a fireside chat featuring company management.
A live webcast will be available on Arcellx's website, and a replay will be accessible for 30 days post-event. Arcellx focuses on innovative cell therapies, including its lead candidate, CART-ddBCMA, targeting relapsed or refractory multiple myeloma, currently in a Phase 2 trial. The FDA has granted it several designations, including Fast Track and Orphan Drug.
FAQ
What is the current stock price of ARCELLX (ACLX)?
What is the market cap of ARCELLX (ACLX)?
